The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression

Journal of Infectious Diseases

Volumn 169, Issue 5, 1994, Pages 968-974

  Richman, Douglas D ^a,b,c   Bozzette, Samuel A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SYNCYTIUM; T LYMPHOCYTE; VIRUS STRAIN;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMAN; LEUKOCYTE COUNT; LONGITUDINAL STUDIES; MALE; PHENOTYPE; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028027078     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.5.968     Document Type: Article

References (37)

1. Barre-Sinoussi F, Chermann JC, Rey R, et al. Isolation of a T-lympho-tropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
2. Popovic M, Sarngadharan MG, Read E, Galio RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
3. Levy JA, Hoffman AD, Kramer AD. Isolation of lymphocytopathic retrovirus from San Francisco patients with AIDS. Science 1984;225:840-2.
4. Wiley CA, Schrier RD. Nelson JA. Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl AcadSci USA 1986;83:7089-93.
5. Asjo B, Albert J, Karlsson A, et al. Replicative properties of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;2:660-2.
6. Anand R, Reed C, Forlenza S. Siegal F, Cheung T, Moore J. Non-cyto-cidal natural variants of human immunodeficiency virus isolated from AIDS patients with neurological disorders. Lancet 1987;2:234-8.
7. Saag MS, Hahn BH, Gibbons J. et al. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988;334:440-4.
8. Meyerhans A, Cheynier R, Albert J, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1992;58:901-10.
9. von Briesen H, Becker WB, Henco K, et al. Isolation frequency and growth properties of HIV variants: Multiple simultaneous variants in a patient demonstrated by molecular cloning. J Med Virol 1987; 23:51-66.
10. Sakai K, Dewhurst S, Ma X, Volsky DJ. Differences in cytopathogeni-city and host cell range among infectious molecular clones of human immunodeficiency virus type I simultaneously from an individual. J Virol 1988;62:4078-85.
11. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type I clones at different stages of infection: Progression of disease is associated with a shift from mono-cytotropic to T-cell-tropic virus populations. J Virol 1992;66:1354-60.
12. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN. Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. Proc Natl Acad Sci USA 1989;86:7200-3.
13. Schuitemaker H, Kootstra NA, de Goede REY, De Wolf F, Miedema F, Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-63.
14. de Jong JJ, Goudsmit J, Keulen W, et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-65.
15. de Jong JJ, de Ronde A, Keulen W, Tersmette M, Goudsmit J Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing (SI) phenotype: Analysis by single amino acid substitution. J Virol 1992;66:6777-80.
16. Fouchier RAM, Groenink M, Kootstra NA, et al. Phenofype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp 120 molecule. J Virol 1992;66:3183-7.
17. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988;240:80-2.
18. Tersmette M, de Goede REY, Al BJM, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-32.
19. Tersmette M, Lange JMA, de Goede REY, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989; 1:983-5.
20. Schellekens PTA, Tersmette M, Roos MTL, et al. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992;6:665-9.
21. Boucher CAB, Lange JMA, Miedema F, et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6:1259-64.
22. Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
23. Phillips AN. CD4 lymphocyte depletion prior to the development of AIDS. AIDS 1992;6:735-6.
24. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
25. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 1990;3:743-6.
26. Bozzette S, McCutchan JA, Spector SA, Wright B, Richman DD. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993;168:1374-79.
27. Richman DD, Johnson VA. Mayers DL, Shirasaka T, O’Brien MC. Mitsuya H. In vitro evaluation of experimental agents for anti-HIV activity. In: Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York: John Wiley & Sons, 1993.
28. Koot M, Vos AHV, Keet RPM, et al. HIV-I biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
29. Computing Resource Center staff. STATA reference manual. 5th ed. Vol 3. Santa Monica, CA: Computing Resource Center, 1992:21926.
30. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothy-midine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
31. Fischl M A, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1009-14.
32. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
33. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 1992; 116:13-20.
34. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
35. Cheeseman SH, Aids Clinical Trials Group 164/165 Study Team. Nevirapine (NVP) alone and in combination with zidovudine [abstract MoB0053], In: Program and abstracts: VIII International Conference on AIDS/III STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992.
36. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990; 112:72737.
37. Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA. Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV. J Clin Invest 1991;87:1710-5.